{"schema_version":"alpha-governance-record-v2","alpha_id":"alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce","ontology_version":"alpha-governance-ontology-v1","as_of":"2026-10-18T06:45:37.209928+00:00","published_at":"2026-10-18T04:48:55.833649+00:00","section":"events","data":{"state":"PUBLISHED","derivation_version":"alpha-governance-event-derivation-v2","events":[{"event_id":"alpha:event:transition:htogvk1ikejf8","event_type":"CEO_CHANGED","effective_at":"2026-02-27","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:person:david-domzalski","alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:10"],"evidence_ids":["alpha:projection-evidence:document:64b2bcbae44ae6a708ba105741252514c6b9662bc62e5ce0956f4e4ad05d3fb0"],"summary":"David Domzalski executive of VYNE Therapeutics Inc., effective 2026-02-27.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:j0qlqc1q1ujuw","event_type":"EXECUTIVE_APPOINTED","effective_at":"2026-02-27","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:person:iain-stuart-ph-d","alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:11"],"evidence_ids":["alpha:projection-evidence:document:5638fd6cf37aaaa2b2124d4908ed2031126ab776e0c7233504acc43f65f45cd0"],"summary":"Iain Stuart, Ph.D. executive of VYNE Therapeutics Inc., effective 2026-02-27.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1mibhrx1qfl4hz","event_type":"GC_CHANGED","effective_at":"2026-02-27","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:person:mutya-harsch","alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:12"],"evidence_ids":["alpha:projection-evidence:document:a6d4e503ee3c1abc84fbd248174c26c831f960ee71149afcf09403157487ba24"],"summary":"Mutya Harsch executive of VYNE Therapeutics Inc., effective 2026-02-27.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1phks5lpqivix","event_type":"CFO_CHANGED","effective_at":"2026-02-27","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:person:tyler-zeronda","alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:13"],"evidence_ids":["alpha:projection-evidence:document:ed1b9c7c1749f9931b244e4e82c1bb6e70d0a3507e2f45913b16f56df5c7504d"],"summary":"Tyler Zeronda executive of VYNE Therapeutics Inc., effective 2026-02-27.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:ijyyq2j6de0y","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:person:david-domzalski","alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:5"],"evidence_ids":["alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166"],"summary":"David Domzalski seat on VYNE Therapeutics Inc., effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1kov4xk1ku3bcg","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:person:patrick-lepore","alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166"],"summary":"Patrick LePore seat on VYNE Therapeutics Inc., effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1dtufc9z66pv7","event_type":"DIRECTOR_APPOINTED","effective_at":"2020-01-01","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:person:sharon-barbari","alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166"],"summary":"Sharon Barbari seat on VYNE Therapeutics Inc., effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:6op5o7jpwc67","event_type":"COMMITTEE_CREATED","effective_at":"2020-01-01","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:committee:vyne-therapeutics-inc:audit-chair-compensation-nominating-and-governance","alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166"],"summary":"Audit · Chair; Compensation; Nominating and Governance committee of VYNE Therapeutics Inc., effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1nwx2j7a1tx7t","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2020-01-01","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:person:sharon-barbari","alpha:committee:vyne-therapeutics-inc:audit-chair-compensation-nominating-and-governance"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:8"],"evidence_ids":["alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166"],"summary":"Sharon Barbari member of Audit · Chair; Compensation; Nominating and Governance, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:92z4f0hzfs94","event_type":"COMMITTEE_CREATED","effective_at":"2020-01-01","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:committee:vyne-therapeutics-inc:nominating-and-governance-chair","alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166"],"summary":"Nominating and Governance · Chair committee of VYNE Therapeutics Inc., effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:el2cbfmcfyzv","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2020-01-01","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:person:patrick-lepore","alpha:committee:vyne-therapeutics-inc:nominating-and-governance-chair"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:7"],"evidence_ids":["alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166"],"summary":"Patrick LePore member of Nominating and Governance · Chair, effective 2020-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1aahac7271quz","event_type":"DIRECTOR_APPOINTED","effective_at":"2019-01-01","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:person:elisabeth-sandoval-little","alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:6"],"evidence_ids":["alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166"],"summary":"Elisabeth Sandoval Little seat on VYNE Therapeutics Inc., effective 2019-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1b2sdz9jx4vhj","event_type":"COMMITTEE_CREATED","effective_at":"2019-01-01","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:committee:vyne-therapeutics-inc:audit-compensation-chair","alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:6"],"evidence_ids":["alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166"],"summary":"Audit; Compensation · Chair committee of VYNE Therapeutics Inc., effective 2019-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:1owv2wp9ug0vv","event_type":"COMMITTEE_MEMBER_ADDED","effective_at":"2019-01-01","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:person:elisabeth-sandoval-little","alpha:committee:vyne-therapeutics-inc:audit-compensation-chair"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:6"],"evidence_ids":["alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166"],"summary":"Elisabeth Sandoval Little member of Audit; Compensation · Chair, effective 2019-01-01.","derivation":"temporal_relationship_change"},{"event_id":"alpha:event:transition:7l1b461xtqp18","event_type":"DIRECTOR_APPOINTED","effective_at":"2015-01-01","detected_at":"2026-10-18T04:48:55.833649+00:00","subject_ids":["alpha:person:steven-basta-2","alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db"],"caused_claim_ids":["alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:9"],"evidence_ids":["alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166"],"summary":"Steven Basta seat on VYNE Therapeutics Inc., effective 2015-01-01.","derivation":"temporal_relationship_change"}]},"claims":[{"id":"alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:5","subject_id":"alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:david-domzalski","object_label":"David Domzalski","object_source_name_forms":[],"value":"David Domzalski: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:david-domzalski","name":"David Domzalski"},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":false,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-18T04:48:55.833649+00:00","sources":[{"id":"alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"VYNE Therapeutics Inc. DEF 14A 2025-11-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925110346/tm2530678-1_def14a.htm","source_date":"2025-11-12","retrieved_at":"2026-04-25T01:04:02.567+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-11-12","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-18T04:48:55.833649+00:00","reviewed_at":"2026-10-18T04:48:55.833649+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:6","subject_id":"alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:elisabeth-sandoval-little","object_label":"Elisabeth Sandoval Little","object_source_name_forms":[],"value":"Elisabeth Sandoval Little: Director, Audit; Compensation · Chair","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:elisabeth-sandoval-little","name":"Elisabeth Sandoval Little"},"title":"Director","role_category":"director","committee":"Audit; Compensation · Chair","is_board_chair":false,"is_independent":true,"start_date":"2019-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2019-01-01","valid_to":null,"recorded_at":"2026-10-18T04:48:55.833649+00:00","sources":[{"id":"alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"VYNE Therapeutics Inc. DEF 14A 2025-11-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925110346/tm2530678-1_def14a.htm","source_date":"2025-11-12","retrieved_at":"2026-04-25T01:04:02.567+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-11-12","effective_from":"2019-01-01","effective_until":null,"observed_at":"2026-10-18T04:48:55.833649+00:00","reviewed_at":"2026-10-18T04:48:55.833649+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:7","subject_id":"alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:patrick-lepore","object_label":"Patrick LePore","object_source_name_forms":[],"value":"Patrick LePore: Director, Nominating and Governance · Chair","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:patrick-lepore","name":"Patrick LePore"},"title":"Director","role_category":"director","committee":"Nominating and Governance · Chair","is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-18T04:48:55.833649+00:00","sources":[{"id":"alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"VYNE Therapeutics Inc. DEF 14A 2025-11-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925110346/tm2530678-1_def14a.htm","source_date":"2025-11-12","retrieved_at":"2026-04-25T01:04:02.567+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-11-12","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-18T04:48:55.833649+00:00","reviewed_at":"2026-10-18T04:48:55.833649+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:8","subject_id":"alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:sharon-barbari","object_label":"Sharon Barbari","object_source_name_forms":[],"value":"Sharon Barbari: Director, Audit · Chair; Compensation; Nominating and Governance","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:sharon-barbari","name":"Sharon Barbari"},"title":"Director","role_category":"director","committee":"Audit · Chair; Compensation; Nominating and Governance","is_board_chair":false,"is_independent":true,"start_date":"2020-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2020-01-01","valid_to":null,"recorded_at":"2026-10-18T04:48:55.833649+00:00","sources":[{"id":"alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"VYNE Therapeutics Inc. DEF 14A 2025-11-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925110346/tm2530678-1_def14a.htm","source_date":"2025-11-12","retrieved_at":"2026-04-25T01:04:02.567+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-11-12","effective_from":"2020-01-01","effective_until":null,"observed_at":"2026-10-18T04:48:55.833649+00:00","reviewed_at":"2026-10-18T04:48:55.833649+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:9","subject_id":"alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db","predicate":"alpha:hasBoardOrCommitteeRole","object_id":"alpha:person:steven-basta-2","object_label":"Steven Basta","object_source_name_forms":[],"value":"Steven Basta: Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"board_seat","person":{"alpha_id":"alpha:person:steven-basta-2","name":"Steven Basta"},"title":"Director","role_category":"director","committee":null,"is_board_chair":false,"is_independent":true,"start_date":"2015-01-01","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2015-01-01","valid_to":null,"recorded_at":"2026-10-18T04:48:55.833649+00:00","sources":[{"id":"alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"VYNE Therapeutics Inc. DEF 14A 2025-11-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925110346/tm2530678-1_def14a.htm","source_date":"2025-11-12","retrieved_at":"2026-04-25T01:04:02.567+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2025-11-12","effective_from":"2015-01-01","effective_until":null,"observed_at":"2026-10-18T04:48:55.833649+00:00","reviewed_at":"2026-10-18T04:48:55.833649+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.85,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:10","subject_id":"alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:david-domzalski","object_label":"David Domzalski","object_source_name_forms":[],"value":"David Domzalski: President, Chief Executive Officer and Director","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:david-domzalski","name":"David Domzalski"},"title":"President, Chief Executive Officer and Director","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-02-27","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-02-27","valid_to":null,"recorded_at":"2026-10-18T04:48:55.833649+00:00","sources":[{"id":"alpha:projection-evidence:document:64b2bcbae44ae6a708ba105741252514c6b9662bc62e5ce0956f4e4ad05d3fb0","identity_scope":"source_document_reference","source_type":"sec_filing","title":"VYNE 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/vyne-20251231.htm","source_date":"2026-02-27T00:00:00+00:00","retrieved_at":"2026-05-16T10:02:50.214733+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-02-27T00:00:00+00:00","effective_from":"2026-02-27","effective_until":null,"observed_at":"2026-10-18T04:48:55.833649+00:00","reviewed_at":"2026-10-18T04:48:55.833649+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:11","subject_id":"alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:iain-stuart-ph-d","object_label":"Iain Stuart, Ph.D.","object_source_name_forms":[],"value":"Iain Stuart, Ph.D.: Chief Scientific Officer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:iain-stuart-ph-d","name":"Iain Stuart, Ph.D."},"title":"Chief Scientific Officer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-02-27","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-02-27","valid_to":null,"recorded_at":"2026-10-18T04:48:55.833649+00:00","sources":[{"id":"alpha:projection-evidence:document:5638fd6cf37aaaa2b2124d4908ed2031126ab776e0c7233504acc43f65f45cd0","identity_scope":"source_document_reference","source_type":"sec_filing","title":"VYNE 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/vyne-20251231.htm","source_date":"2026-02-27T00:00:00+00:00","retrieved_at":"2026-05-16T10:02:51.162699+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-02-27T00:00:00+00:00","effective_from":"2026-02-27","effective_until":null,"observed_at":"2026-10-18T04:48:55.833649+00:00","reviewed_at":"2026-10-18T04:48:55.833649+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:12","subject_id":"alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:mutya-harsch","object_label":"Mutya Harsch","object_source_name_forms":[],"value":"Mutya Harsch: Chief Legal Officer, General Counsel and Secretary","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:mutya-harsch","name":"Mutya Harsch"},"title":"Chief Legal Officer, General Counsel and Secretary","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-02-27","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-02-27","valid_to":null,"recorded_at":"2026-10-18T04:48:55.833649+00:00","sources":[{"id":"alpha:projection-evidence:document:a6d4e503ee3c1abc84fbd248174c26c831f960ee71149afcf09403157487ba24","identity_scope":"source_document_reference","source_type":"sec_filing","title":"VYNE 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/vyne-20251231.htm","source_date":"2026-02-27T00:00:00+00:00","retrieved_at":"2026-05-16T10:02:51.676514+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-02-27T00:00:00+00:00","effective_from":"2026-02-27","effective_until":null,"observed_at":"2026-10-18T04:48:55.833649+00:00","reviewed_at":"2026-10-18T04:48:55.833649+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"},{"id":"alpha:claim:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db:leadership_role:13","subject_id":"alpha:company:c4b8ab8d-bb60-4a00-85a2-a97036fd46db","predicate":"alpha:hasExecutiveRole","object_id":"alpha:person:tyler-zeronda","object_label":"Tyler Zeronda","object_source_name_forms":[],"value":"Tyler Zeronda: Chief Financial Officer and Treasurer","claim_type":"leadership_role","predicate_id":"alpha:predicate:leadership_role","predicate_version":1,"machine_key":"leadership_role","human_label":"Leadership Role","governed_predicate":true,"machine_value":{"kind":"executive_role","person":{"alpha_id":"alpha:person:tyler-zeronda","name":"Tyler Zeronda"},"title":"Chief Financial Officer and Treasurer","role_category":"executive","committee":null,"is_board_chair":false,"is_independent":null,"start_date":"2026-02-27","end_date":null},"corroboration_count":1,"source_claim_count":1,"valid_from":"2026-02-27","valid_to":null,"recorded_at":"2026-10-18T04:48:55.833649+00:00","sources":[{"id":"alpha:projection-evidence:document:ed1b9c7c1749f9931b244e4e82c1bb6e70d0a3507e2f45913b16f56df5c7504d","identity_scope":"source_document_reference","source_type":"sec_filing","title":"VYNE 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/vyne-20251231.htm","source_date":"2026-02-27T00:00:00+00:00","retrieved_at":"2026-05-16T10:02:50.692652+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"source_date":"2026-02-27T00:00:00+00:00","effective_from":"2026-02-27","effective_until":null,"observed_at":"2026-10-18T04:48:55.833649+00:00","reviewed_at":"2026-10-18T04:48:55.833649+00:00","verified_at":null,"verification_state":"source_reported","legacy_verification_label":"confirmed","review_state":"none","confidence":0.94,"assertion_type":"source_reported","evidence_state":"linked","publication_state":"PUBLISHED","record_version":"public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce"}],"evidence":[{"id":"alpha:projection-evidence:document:bc1de32e02283f7009f46cff6e49ffe1de637f4c83c1f24e77f1f3b2a8f35166","identity_scope":"source_document_reference","source_type":"sec_proxy","title":"VYNE Therapeutics Inc. DEF 14A 2025-11-12","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000110465925110346/tm2530678-1_def14a.htm","source_date":"2025-11-12","retrieved_at":"2026-04-25T01:04:02.567+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:64b2bcbae44ae6a708ba105741252514c6b9662bc62e5ce0956f4e4ad05d3fb0","identity_scope":"source_document_reference","source_type":"sec_filing","title":"VYNE 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/vyne-20251231.htm","source_date":"2026-02-27T00:00:00+00:00","retrieved_at":"2026-05-16T10:02:50.214733+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:5638fd6cf37aaaa2b2124d4908ed2031126ab776e0c7233504acc43f65f45cd0","identity_scope":"source_document_reference","source_type":"sec_filing","title":"VYNE 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/vyne-20251231.htm","source_date":"2026-02-27T00:00:00+00:00","retrieved_at":"2026-05-16T10:02:51.162699+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:a6d4e503ee3c1abc84fbd248174c26c831f960ee71149afcf09403157487ba24","identity_scope":"source_document_reference","source_type":"sec_filing","title":"VYNE 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/vyne-20251231.htm","source_date":"2026-02-27T00:00:00+00:00","retrieved_at":"2026-05-16T10:02:51.676514+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}},{"id":"alpha:projection-evidence:document:ed1b9c7c1749f9931b244e4e82c1bb6e70d0a3507e2f45913b16f56df5c7504d","identity_scope":"source_document_reference","source_type":"sec_filing","title":"VYNE 10-K executive officers","publisher":null,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000156604426000002/vyne-20251231.htm","source_date":"2026-02-27T00:00:00+00:00","retrieved_at":"2026-05-16T10:02:50.692652+00:00","locator":null,"use_rights":{"schema_version":"alpha-source-use-rights-v1","classification":"unknown","public_retrieval":"not_specified","agent_retrieval":"not_specified","redistribution":"not_granted","derived_use":"not_specified","model_training":"not_granted","retention":"not_specified","attribution_required":null,"license_id":null,"terms_url":null,"reviewed_at":null,"derivation":"fail_closed_unknown"}}],"coverage_state":"PUBLISHED","quality":{"schema_version":"alpha-record-quality-v2","overall":0.836,"status":"strong","publication_readiness":"ready","dimensions":{"identity":1,"coverage":0.5,"freshness":1,"evidence_completeness":1,"source_authority":0.887,"cross_source_agreement":0.75,"temporal_completeness":0.563},"diagnostics":{"published_claims":23,"factual_claims":23,"claims_with_linked_evidence":23,"disputed_claims":0,"conflicts":0,"stale_claims":0,"stale_claim_ids":[],"temporal_claims":16,"temporal_claims_with_valid_from":9,"missing_coverage_sections":["governance","financials","workforce","ownership","ratings"],"missing_expected_claims":["headquarters","official_website","financial_metric","governance_document","ownership","auditor","legal_matter","risk","ai_governance"]},"derivation":"deterministic_record_projection"},"publication":{"state":"PUBLISHED","published_at":"2026-10-18T04:48:55.833649+00:00","observed_at":"2026-10-18T04:48:55.833649+00:00","reviewed_at":"2026-10-18T04:48:55.833649+00:00","verified_at":"2026-10-18T04:48:55.833649+00:00"},"verification":{"schema_version":"alpha-verification-states-v1","state":"source_reported","identity_ownership":"unclaimed","assurance_level":null,"claim_state_counts":{"source_reported":23,"corroborated":0,"alpha_verified":0,"disputed":0,"superseded":0},"derivation":"claim_states+identity_ownership","summary":"Published claims are reported by public sources; none is Alpha verified. Profile ownership is unclaimed.","facets":[{"facet":"identity","state":"unclaimed"},{"facet":"evidence","state":"source_reported"},{"facet":"evaluation","state":"not_evaluated"},{"facet":"monitoring","state":null},{"facet":"authority","state":null},{"facet":"freshness","state":"current"}]},"rights":{"public_retrieval":"allowed","agent_retrieval":"allowed","redistribution":"not_granted","model_training":"not_granted","commercial_use":"not_specified","relationship_pathfinding":"not_granted","direct_contact":"not_granted"},"resource":{"uri":"alpha://company/vyne-therapeutics-inc/events","section":"events","href":"https://registry.alpha.ac/api/public/companies/vyne-therapeutics-inc?format=record&section=events","media_type":"application/json","availability":"contract"},"limitations":["Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.","Only explicitly published canonical company identity and current confirmed public roles are included.","Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.","Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.","This Company Profile is an identity and evidence record, not an Alpha rating."]}